tbuckley/cabot-search huggingface dataset:
Photodynamic acidification therapy to reduce triple negative breast cancer growth in vivo.
Authors: Nuha Buchanan Kadri, Matthew Gdovin, Nizar Alyassin, Justin Avila, Aryana Cruz, Louis Cruz, Steve Holliday, Zachary Jordan, Cameron Ruiz, Jennifer Watts
Journal: Journal of Clinical Oncology (2016)

e12574 Background: Breast cancer, though much researched, continues to claim the lives of more than half a million women worldwide each year; triple negative breast cancer (TNBC) accounts for 15-25% of these mortalities. Treatment options for TNBC are limited to surgery, radiation, and a select few chemotherapies, to which the cancer often becomes resistant. Cancer cells maintain a more basic intracellular pH (pHi ) than healthy cells, making disruption of pH dynamics a potential target for treatment. The ability to induce a decrease of pHi, in a focal manner, would allow for treatment of cancers with a poor response to standard treatments or in cases where standard therapy is not feasible due to comorbidities or the location of the tumor. Methods: In our lab we were able to drop pHi in MDA-MB-231 TNBC, leading to apoptosis, using a photosensitizing agent in vitro. This technique was then tested in vivo using MDA-MB-231 TNBC cells in mice; cells were injected into the mammary fat-pads of athymic female mice. We allowed tumors to grow to 5 mm before we administered a single photodynamic treatment to induce acidification. Subsequently, we conducted a multiple treatment experiment in which we administered photodynamic treatment at regular intervals. Results: Both the single treatment and multiple treatment cohorts showed the tumor growth rate was significantly suppressed and survivability significantly increased. Conclusions: These results show promise for our photodynamic agent as a potential treatment for cancer. Future studies will examine the use of nanoparticles with multiple layers of selectivity as a vehicle for drug delivery in a systemic manner. Additionally, we will examine the efficacy of our photodynamic therapy in other types of drug-resistant and recalcitrant cancers. Supported by UTSA Collaborative Research Seed Grant Program Grant awarded to MJG
Genealogy of the L2C Leukemia “Lines” in the Strain 2 Guinea Pig
Authors: Eli M. Nadel
Journal: JNCI Journal of the National Cancer Institute (1977)

Journal Article Genealogy of the L2C Leukemia “Lines” in the Strain 2 Guinea Pig Get access Eli M. Nadel, M.D. Eli M. Nadel, M.D. Saint Louis University, School of Medicine, Saint Louis, Missouri 63104 Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 58, Issue 5, May 1977, Page 1183, https://doi.org/10.1093/jnci/58.5.1183 Published: 01 May 1977
Natural killer cells contribute to hepatic injury and help in viral persistence during progression of hepatitis B e-antigen-negative chronic hepatitis B virus infection
Authors: S. Ghosh, M. Nandi, S. Pal, D. Mukhopadhyay, B.C. Chakraborty, M. Khatun, D. Bhowmick, R.K. Mondal, S. Das, K. Das, R. Ghosh, S. Banerjee, A. Santra, M. Chatterjee, A. Chowdhury, S. Datta
Journal: Clinical Microbiology and Infection (2016)
Alexithymic features in relation to the dexamethasone suppression test in a Finnish population sample
Authors: T Lindholm, V Lehtinen, M T Hyyppä, P Puukka
Journal: American Journal of Psychiatry (1990)

Hypothesizing that a positive DST result could reflect an aberrant stress reaction in subjects with alexithymic features, the authors investigated the relationship between alexithymic features and DST results in 266 subjects from a Finnish adult population sample. Alexithymic features were assessed with the Beth Israel Questionnaire. The authors found a statistically significant association between observed alexithymic features and a positive DST result. This association could be seen after adjustment separately for age, social rank, marital status, and the occurrence of depression.
Accelerated breast MRI for breast cancer screening.
Authors: Christiane K. Kuhl, Simone Schrading, Kevin Strobel, Heribert Bieling
Journal: Journal of Clinical Oncology (2013)

1 Background: Current breast MRI protocols are designed for diagnostic, not for screening purposes, and are therefore time consuming to acquire and to read. We investigated whether an abridged breast MRI protocol, consisting only of the first post contrast subtracted (FAST) images and their maximum intensity projection (MIP), would be suitable for screening purposes. Idea was to trade some of the very high sensitivity of breast MRI for acquisition and interpretation speed. Long term goal is to increase the access to breast MRI by reducing the cost associated with the examination. Methods: 443 women at increased risk of breast cancer, with negative digital mammography, underwent 606 breast MRI screening studies. Images were prospectively read by experienced breast radiologists. Readers were asked to first review the MIPs and search for significant enhancement, then to evaluate the FAST images for possible further categorization of enhancement, and only thereafter, to analyse the full diagnostic breast MRI protocol. We compared diagnostic yield and accuracy of MIP and of FAST readings vs. that of the full protocol. Results: MR table time for the full protocol was 21 minutes, table time for FAST images and MIPs was under 3 minutes. Average time to read MIP and FAST image was 2.8 seconds and 28 seconds, respectively. A total 11 breast cancers (4 DCIS, 7 invasive, median size 8 mm, all intermediate or high grade), were diagnosed in the 603 examinations for an additional cancer yield of 18.2/1000. MIPs were positive in 9/11 (82%); FAST readings as well as the full protocol were positive in 10/11 (91%). NPV of the MIP and FAST readings was 99.6% (484/486) and 99.8%, respectively. Specificity of FAST readings was equivalent to that of the full protocol (94.4%), with 33 vs. 35 false-positive diagnoses. Conclusions: In this high risk screening cohort, an MR table time of 3 minutes and an expert radiologist reading time of 2 seconds for the interpretation of the MIP image was sufficient to establish absence of breast cancer with a negative predictive value of 99.6%. With the same abridged MR protocol and an expert reading time of under 30 seconds for interpretation of FAST images, sensitivity and specificity was identical to that of the full protocol, allowing an additional cancer yield of 18.2/1,000.
Human Myelogenous (Ph 1 +) Leukemia Cell Line: Into Athymic Mice 2
Authors: Bismarck B. Lozzio, Carmen B. Lozzio, Emilio Machado
Journal: JNCI Journal of the National Cancer Institute (1976)

Journal Article Human Myelogenous (Ph1+) Leukemia Cell Line: Into Athymic Mice Get access Bismarck B. Lozzio, Bismarck B. Lozzio 3Laboratory of Experimental Hematology, The University of Tennessee Memorial Research Center, Center for Health Sciences, Knoxville, Tenn. 37920. Search for other works by this author on: Oxford Academic PubMed Google Scholar Carmen B. Lozzio, Carmen B. Lozzio 4Laboratory of Medical Genetics, The University of Tennessee Memorial Research Center. Search for other works by this author on: Oxford Academic PubMed Google Scholar Emilio Machado Emilio Machado 5Laboratory of Experimental Pathology, The University of Tennessee Memorial Research Center. 6The competent technical assistance of Mrs. Jinhi Kim, Mrs. Cynthia Smith, Mrs. Dusica Susic, Mr. Stephen Lair, and Mr. Rafael Perez is gratefully acknowledged. Search for other works by this author on: Oxford Academic PubMed Google Scholar JNCI: Journal of the National Cancer Institute, Volume 56, Issue 3, March 1976, Pages 627–629, https://doi.org/10.1093/jnci/56.3.627 Published: 01 March 1976 Article history Received: 07 July 1975 Accepted: 21 October 1975 Published: 01 March 1976
Life Expectancy of Patients With Chronic Myeloid Leukemia Approaches the Life Expectancy of the General Population
Authors: Hannah Bower, Magnus Björkholm, Paul W. Dickman, Martin Höglund, Paul C. Lambert, Therese M.-L. Andersson
Journal: Journal of Clinical Oncology (2016)

A dramatic improvement in the survival of patients with chronic myeloid leukemia (CML) occurred after the introduction of imatinib mesylate, the first tyrosine kinase inhibitor (TKI). We assessed how these changes affected the life expectancy of patients with CML and life-years lost as a result of CML between 1973 and 2013 in Sweden.
Analysis of <i>BRAF</i>, <i>NRAS</i>, <i>cKIT, </i>and <i>EGFR </i>alterations in melanoma lung metastases.
Authors: Alessandra Ulivieri, Giuseppe Cardillo, Liborio Manente, Andrea Petricca Mancuso, Leonardo Vigna, Rita Gasbarra, Alvaro Leone
Journal: Journal of Clinical Oncology (2012)

e19033 Background: About 25% of pts will eventually develop lung metastases from primary melanoma. Activating mutations in BRAF, NRAS, CKIT and EGFR genes are involved in melanoma progression. Trials with drugs targeting oncogenic BRAF in melanoma have shown that a V600E mutation may identify a subgroup of pts with a high response rate. Methods: We analysedtheprevalence of BRAF, NRAS and CKIT mutations by direct sequencing and of EGFR copy number alterations by FISH, in pts affected by melanoma lung metastases, and explored their correlation with lung metastasis-free survival (LMFS) and post surgical progression-free survival (psPFS). Results: Over 10 years, 33 cases of pts with melanoma lung metastases were diagnosed at our institution, of which 22 underwent surgery with curative intent. The mean age was 64 years, and 19 (57.5%) were male. 51% carried a BRAF V600E mutation while 18% had a NRAS codon 61 mutation. The two events were mutually exclusive. No alterations were observed in exon 11 of the CKIT gene. FISH analysis indicated an EGFR low amplification in 3 cases and chromosome 7 polysomy in 13 cases. The presence of a BRAF V600E mutation was associated with a longer LMFS (median 6.1 vs 4.4 years, p&lt;0.05), but it had no impact on psPFS (26.9 vs 29.6 months, p=0.6). NRAS mutations were associated with a reduction in both LMFS (3.7 years vs 4.7 years, p = 0.008) and, more significantly, in psPFS (12,5 months vs 41,1 months, p = 0.005; hazard ratio, 2.7). Conclusions: The frequency of mutations in BRAF (51%) and NRAS (18%) observed in lung metastatic melanomas was similar to the rates reported in other metastatic sites. BRAF mutations don't appear to be related with a more aggressive clinical course, while NRAS might be an independent negative prognostic factor after resection of melanoma lung metastases. The presence of BRAF mutations should be tested in melanoma lung metastases to identify the patients eligible for anti BRAF targeted therapy.
Reduction by Phenformin of Excessive Insulin Levels After Glucose Loading in Obese and Diabetic Subjects
Authors: G M GRODSKY, J H KARAM, F C PAVLATOS, P H FORSHAM
Journal: JAMA (1963)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA HomeNew OnlineCurrent IssueFor Authors Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) Podcasts Clinical Reviews Editors' Summary Medical News Author Interviews More JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA journal
Anal human papillomavirus and HIV: An exploratory study among men who have sex with men in Moscow, Russia
Authors: AL Wirtz, CE Zelaya, A Peryshkina, I McGowan, RD Cranston, C Latkin, G D’Souza, N Galai, V Mogilniy, P Dzhigun, I Kostetskaya, C Beyrer
Journal: Eurosurveillance (2015)

Anal human papillomavirus (HPV) is prevalent among men who have sex with men (MSM), but has not been studied in the Russian Federation. HIV seropositive (N=58) and seronegative MSM (N=65) were enrolled in a cross-sectional study in Moscow, Russia, surveyed, and underwent anal cytology and anal HPV genotyping. Multivariable logistic regression was performed to identify correlates of infection with oncogenic HPV genotypes 16 and/or 18 (HPV 16/18). Some 39.5% of all MSM were infected with at least one anal HPV genotype, 31.7% with HPV16/18, and 11.7% had high grade squamous intraepithelial lesion (HSIL). HPV 16/18 was more prevalent among HIV seropositive than seronegative men (41.4% vs. 23.1%; p=0.03). In the final multivariable model, HIV infection was independently associated with HPV 16/18 (AOR:5.08; 95%CI:1.49–17.34), as were migration to/within Russia (AOR:3.18; 95%CI:1.00–10.09) and having 2–4 steady male sex partners in the last year (vs. ≤1 partner; AOR:6.99; 95%CI:1.94–25.24). History of jail/prison and use of incompatible lubricants were marginally associated with HPV 16/18 (p<0.10). Anal HPV 16/18 was prevalent among this sample of Moscow-based MSM and strongly associated with HIV infection. Correlations with mobility and detention in prison/jail, likely reflect behavioural risk and low healthcare access among marginalized populations that limits access to HIV/STI prevention options. Comprehensive prevention options are needed for MSM in Russia and may benefit from inclusion of young men in piloted HPV vaccination programs.
Programmed Death-1 Blockade With Pembrolizumab in Patients With Classical Hodgkin Lymphoma After Brentuximab Vedotin Failure
Authors: Philippe Armand, Margaret A. Shipp, Vincent Ribrag, Jean-Marie Michot, Pier Luigi Zinzani, John Kuruvilla, Ellen S. Snyder, Alejandro D. Ricart, Arun Balakumaran, Shelonitda Rose, Craig H. Moskowitz
Journal: Journal of Clinical Oncology (2016)

Purpose Classical Hodgkin lymphoma (HL) frequently exhibits genetic alterations leading to overexpression of the programmed death-1 (PD-1) ligands, suggesting a possible vulnerability to PD-1 blockade. The phase Ib study KEYNOTE-013 (NCT01953692) tested the safety and efficacy of the anti–PD-1 antibody pembrolizumab in patients with hematologic malignancies. Based on its genetics, HL was included as an independent cohort. Methods We enrolled patients with relapsed or refractory HL whose disease progressed on or after treatment with brentuximab vedotin. Patients received pembrolizumab, 10 mg/kg every 2 weeks, until disease progression occurred. Response to treatment was assessed at week 12 and every 8 weeks thereafter. Principal end points were safety and complete remission (CR) rate. Results Thirty-one patients were enrolled; 55% had more than four lines of prior therapy, and 71% had relapsed after autologous stem cell transplantation. Five patients (16%) experienced grade 3 drug-related adverse events (AEs); there were no grade 4 AEs or deaths related to treatment. The CR rate was 16% (90% CI, 7% to 31%). In addition, 48% of patients achieved a partial remission, for an overall response rate of 65% (90% CI, 48% to 79%). Most of the responses (70%) lasted longer than 24 weeks (range, 0.14+ to 74+ weeks), with a median follow-up of 17 months. The progression-free survival rate was 69% at 24 weeks and 46% at 52 weeks. Biomarker analyses demonstrated a high prevalence of PD-L1 and PD-L2 expression, treatment-induced expansion of T cells and natural killer cells, and activation of interferon-γ, T-cell receptor, and expanded immune-related signaling pathways. Conclusions Pembrolizumab was associated with a favorable safety profile. Pembrolizumab treatment induced favorable responses in a heavily pretreated patient cohort, justifying further studies.
Newly Synthesized Indolylmalemide PDA-66 and Its Derivates Induce Antiproliferative Effects In Acute Lymphoblastic Leukemia
Authors: Catrin Roolf, Christin Kretzschmar, Tina-Susann Langhammer, Anett Sekora, Anahit Pews-Davtyan, Matthias Beller, Arndt Rolfs, Mathias Freund, Christian Junghanss
Journal: Blood (2013)
The Use of Gene-Expression Profiling to Predict Outcome of Follicular Lymphoma Patients Treated with Rituximab and Chemotherapy.
Authors: Antti Harjunpää, Matti Nykter, Outi Monni, Marja-Liisa Karjalainen-Lindsberg, Samuli Hemmer, Olli Yli-Harja, Seppo Meri, Sirpa Leppä
Journal: Blood (2004)
Mucosal expression of DEC-205 targeted allergen alleviates an asthmatic phenotype in mice
Authors: A. Maaske, F.C. Devos, T. Niezold, D. Lapuente, A. Tannapfel, J.A. Vanoirbeek, K. Überla, M. Peters, M. Tenbusch
Journal: Journal of Controlled Release (2016)

Considering the rising incidence of allergic asthma, the symptomatic treatments that are currently applied in most cases are less than ideal. Specific immunotherapy is currently the only treatment that is able to change the course of the disease, but suffers from a long treatment duration. A gene based immunization that elicits the targeting of allergens towards dendritic cells in a steady-state environment might have the potential to amend these difficulties. Here we used a replication deficient adenovirus to induce the mucosal expression of OVA coupled to a single-chain antibody against DEC-205. A single intranasal vaccination was sufficient to mitigate an OVA-dependent asthmatic phenotype in a murine model. Invasive airway measurements demonstrated improved lung function after Ad-Dec-OVA treatment, which was in line with a marked reduction of goblet cell hyperplasia and lung eosinophilia. Furthermore OVA-specific IgE titers and production of type 2 cytokines were significantly reduced. Together, the here presented data demonstrate the feasibility of mucosal expression of DEC-targeted allergens as a treatment of allergic asthma.
Is Briquet's syndrome a heterogeneous disorder?
Authors: B Liskow, E Othmer, E C Penick, C DeSouza, W Gabrielli
Journal: American Journal of Psychiatry (1986)

A structured interview that identified 78 female psychiatric outpatients as having Briquet's syndrome also indicated that 77 of the 78 fulfilled inclusive diagnostic criteria for one or more other psychiatric syndromes. If, as this finding suggests, Briquet's syndrome represents a heterogeneous disorder, its various components should be evaluated and patient responses to treatments should be assessed. Until such studies are done, the general and psychiatric physician should be aware that the diagnosis of Briquet's syndrome does not rule out the possibility of other psychiatric illnesses that may be more amenable to treatment.
Neuroblastoma in the bone marrow
Authors: Edward Renaudon‐Smith, Marc Arca, Akwasi Osei‐Yeboah, Leena Karnik, Barbara J. Bain
Journal: American Journal of Hematology (2016)

A 4-year-old girl presented to her local hospital with a three-week history of intermittent fevers, right hip pain, and walking with a limp. Blood tests showed: raised inflammatory markers (C-reactive protein 203 mg/l, erythrocyte sedimentation rate 118 mm in 1 h), white cell count 12.1 × 109/l, hemoglobin concentration 98 g/l, mean cell volume 71 fl, platelets 373 × 109/l, neutrophils 6.9 × 109/l and lymphocytes 4.1 × 109/l. Ultrasound of the right hip did not show any effusion. She was commenced on ceftriaxone and clindamycin for possible osteomyelitis and transferred to our center for further investigation. Magnetic resonance imaging of the right hip and pelvis showed a diffuse abnormal bone marrow signal involving all of the bones imaged, suggesting a malignant process involving the bone marrow. The blood count was similar to previously and a blood film showed rouleaux, platelet clumps and 12% large granular lymphocytes. Bone marrow aspiration was difficult and the bone was noted to be abnormally firm. Films of the aspirate showed that normal hemopoietic cells were almost entirely replaced by an infiltrate of neoplastic cells. These were mainly small cells with a high nucleocytoplasmic ratio and agranular, moderately basophilic cytoplasm. There were some cytological similarities to leukemic blast cells but the correct diagnosis was revealed by the presence of abundant neurofibrillary bundles (left image). Other cytological features indicative of the diagnosis of neuroblastoma were the presence of some much larger, multinucleated cells (top of left image), the presence of rosettes of neoplastic cells around fibrillar material, the molding of nuclei by the nuclei of adjacent cells (left image) and the presence of occasional cells from which neurofibrils could be seen to emerge (right image). It is of interest that nuclear molding is also characteristic of small cell carcinoma of the lung, a tumor that is likewise of neuroendocrine origin. Immunophenotyping confirmed involvement by a non-hematological neoplasm (CD45 negative, CD56 positive, CD9 positive, CD99 negative). A bone marrow trephine biopsy and immunohistochemistry confirmed the aspirate diagnosis. Computed tomography of the chest and abdomen revealed a calcified mass anterior to the left kidney with enlarged left para-aortic and right axillary lymph nodes, in keeping with the bone marrow diagnosis of neuroblastoma. A further interesting and potentially significant finding was the fact that the patient was highly sensitive to opiates with apnea and oxygen desaturation with a relatively low dose of oral morphine (180 μg/kg). Congenital hypoventilation syndrome, so called Ondine's curse, is associated with a mutation in the Paired-like Homeobox 2b (PHOX2B) gene, which is involved in the prenatal development of the autonomic nervous system and is also linked to the development of neuroblastoma. Gene mutational analysis will be performed in our patient to investigate this further.